VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

[1]  P. Patnaik,et al.  Mass spectrometry , 2018, Environmental Chemical Analysis.

[2]  V. Torri,et al.  SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. , 2012, Journal of proteomics.

[3]  Paul Dowling,et al.  Analysis of acute‐phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer , 2012, International journal of cancer.

[4]  I. Floriani,et al.  Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  David Venet,et al.  Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome , 2011, PLoS Comput. Biol..

[6]  Charles A Powell,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. , 2011, Proceedings of the American Thoracic Society.

[7]  J. Hainsworth,et al.  Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial , 2011, The Lancet.

[8]  S. Barni,et al.  PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  O. Hoekstra,et al.  First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  T. Dang,et al.  VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. , 2010, Lung cancer.

[12]  W. Akerley,et al.  Bevacizumab/erlotinib (BEER) as first-line treatment for untreated, advanced non-squamous non-small cell lung cancer (NSNSCLC). , 2010 .

[13]  E. Giovannetti,et al.  A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[14]  D. Carbone,et al.  Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503 , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  R. Caprioli,et al.  Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[16]  R. Gray,et al.  Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. , 2007, Journal of the National Cancer Institute.

[17]  D. Haber,et al.  Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  V. Kovač,et al.  Erlotinib in previously treated non-small-cell lung cancer , 2006 .

[19]  M. Kokubun,et al.  Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[20]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[21]  R. Herbst,et al.  Angiogenesis and lung cancer: prognostic and therapeutic implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Bill C. White,et al.  Proteomic patterns of tumour subsets in non-small-cell lung cancer , 2003, The Lancet.

[23]  W. Travis.  Pathology of lung cancer. , 2002, Clinics in chest medicine.

[24]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[25]  M. Pras,et al.  Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. , 1986, Journal of clinical pathology.

[26]  L. Bubendorf,et al.  VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. , 2013, Lung cancer.

[27]  国分 正恵.  Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio , 2006 .

[28]  L. Ellis,et al.  Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.